Want to see BBIO full AI Analyst Report?
BridgeBio Pharma (BBIO) Ratios
BridgeBio Pharma Ratios
BBIO's free cash flow for Q3 2026 was $-44.46M. For the 2026 fiscal year, BBIO's free cash flow was decreased by $-290.00K and operating cash flow was $-44.17M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.62 | 4.67 | 3.32 | 4.52 | 6.58 |
| Quick Ratio | 2.52 | 4.67 | 3.32 | 4.52 | 6.58 |
| Cash Ratio | 1.98 | 4.41 | 2.61 | 3.10 | 2.92 |
| Solvency Ratio | -0.24 | -0.22 | -0.34 | -0.25 | -0.30 |
| Operating Cash Flow Ratio | -1.55 | -3.37 | -3.67 | -3.45 | -3.69 |
| Short-Term Operating Cash Flow Coverage | -25.61 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -2.26B | $ -1.66B | $ -1.41B | $ -1.32B | $ -989.51M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 2.92 | 1.88 | 3.18 | 2.77 | 1.70 |
| Debt-to-Equity Ratio | -1.31 | -1.18 | -1.28 | -1.37 | -1.98 |
| Debt-to-Capital Ratio | 4.18 | 6.59 | 4.51 | 3.68 | 2.02 |
| Long-Term Debt-to-Capital Ratio | 4.29 | 6.79 | 4.64 | 3.77 | 2.04 |
| Financial Leverage Ratio | -0.45 | -0.63 | -0.40 | -0.50 | -1.16 |
| Debt Service Coverage Ratio | -9.60 | -4.41 | -6.96 | -4.94 | -11.41 |
| Interest Coverage Ratio | -10.72 | -5.97 | -7.47 | -6.37 | -12.33 |
| Debt to Market Cap | 0.18 | 0.34 | 0.26 | 1.52 | 0.71 |
| Interest Debt Per Share | 14.10 | 9.83 | 11.19 | 12.23 | 12.28 |
| Net Debt to EBITDA | -3.19 | -2.40 | -2.41 | -3.39 | -2.50 |
| Profitability Margins | |||||
| Gross Profit Margin | 94.37% | 98.25% | 73.71% | 95.58% | 95.53% |
| EBIT Margin | -135.81% | -199.59% | -6148.15% | -520.57% | -774.11% |
| EBITDA Margin | -134.73% | -196.86% | -6078.34% | -511.85% | -765.73% |
| Operating Profit Margin | -113.35% | -267.22% | -6528.75% | -659.65% | -827.12% |
| Pretax Profit Margin | -146.39% | -244.34% | -7021.94% | -624.17% | -841.20% |
| Net Profit Margin | -145.26% | -241.44% | -6913.92% | -619.70% | -806.90% |
| Continuous Operations Profit Margin | -146.50% | -244.86% | -7021.94% | -624.17% | -841.20% |
| Net Income Per EBT | 99.23% | 98.81% | 98.46% | 99.28% | 95.92% |
| EBT Per EBIT | 129.15% | 91.44% | 107.55% | 94.62% | 101.70% |
| Return on Assets (ROA) | -77.92% | -58.28% | -117.72% | -77.23% | -55.54% |
| Return on Equity (ROE) | 35.12% | 36.50% | 47.49% | 38.35% | 64.63% |
| Return on Capital Employed (ROCE) | -87.81% | -77.52% | -150.89% | -102.11% | -65.70% |
| Return on Invested Capital (ROIC) | -108.46% | -77.07% | -149.35% | -101.37% | -65.33% |
| Return on Tangible Assets | -80.32% | -59.83% | -123.68% | -80.96% | -58.12% |
| Earnings Yield | -4.83% | -10.49% | -9.79% | -42.82% | -23.36% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.60 | 46.99 | 5.31 | 4.55 | 3.53 |
| Payables Turnover | 0.78 | 0.40 | 0.23 | 0.30 | 0.26 |
| Inventory Turnover | 1.06 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 37.15 | 17.37 | 0.47 | 3.08 | 1.52 |
| Asset Turnover | 0.54 | 0.24 | 0.02 | 0.12 | 0.07 |
| Working Capital Turnover Ratio | 0.97 | 0.49 | 0.02 | 0.13 | 0.11 |
| Cash Conversion Cycle | -20.95 | -897.49 | -1521.27 | -1148.22 | -1289.56 |
| Days of Sales Outstanding | 101.37 | 7.77 | 68.70 | 80.28 | 103.40 |
| Days of Inventory Outstanding | 345.38 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 467.70 | 905.25 | 1589.97 | 1228.50 | 1392.95 |
| Operating Cycle | 446.75 | 7.77 | 68.70 | 80.28 | 103.40 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.26 | -2.80 | -3.24 | -2.84 | -3.45 |
| Free Cash Flow Per Share | -2.27 | -2.80 | -3.25 | -2.89 | -3.78 |
| Dividend Paid and CapEx Coverage Ratio | -406.48 | -558.12 | -404.07 | -66.37 | -10.32 |
| Capital Expenditure Coverage Ratio | -406.48 | -558.12 | -404.07 | -66.37 | -10.32 |
| Operating Cash Flow Coverage Ratio | -0.16 | -0.30 | -0.30 | -0.24 | -0.29 |
| Operating Cash Flow to Sales Ratio | -0.89 | -2.35 | -56.73 | -5.40 | -7.14 |
| Free Cash Flow Yield | -2.96% | -10.22% | -8.05% | -37.89% | -22.68% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -20.18 | -9.53 | -10.22 | -2.34 | -4.28 |
| Price-to-Sales (P/S) Ratio | 30.05 | 23.01 | 706.43 | 14.47 | 34.54 |
| Price-to-Book (P/B) Ratio | -7.27 | -3.48 | -4.85 | -0.90 | -2.77 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -33.75 | -9.79 | -12.42 | -2.64 | -4.41 |
| Price-to-Operating Cash Flow Ratio | -33.83 | -9.81 | -12.45 | -2.68 | -4.84 |
| Price-to-Earnings Growth (PEG) Ratio | -0.64 | 0.35 | -0.57 | 0.10 | -0.53 |
| Enterprise Value Multiple | -25.49 | -14.09 | -14.03 | -6.22 | -7.01 |
| Enterprise Value | 17.25B | 6.16B | 7.94B | 2.47B | 3.74B |
| EV to EBITDA | -25.49 | -14.09 | -14.03 | -6.22 | -7.01 |
| EV to Sales | 34.35 | 27.74 | 853.04 | 31.82 | 53.65 |
| EV to Free Cash Flow | -38.58 | -11.80 | -15.00 | -5.80 | -6.85 |
| EV to Operating Cash Flow | -38.67 | -11.82 | -15.04 | -5.89 | -7.51 |
| Tangible Book Value Per Share | -10.67 | -7.96 | -8.41 | -8.64 | -6.31 |
| Shareholders’ Equity Per Share | -10.53 | -7.89 | -8.32 | -8.51 | -6.03 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 2.55 | 1.19 | 0.06 | 0.53 | 0.48 |
| Net Income Per Share | -3.70 | -2.88 | -3.95 | -3.26 | -3.90 |
| Tax Burden | 0.99 | 0.99 | 0.98 | 0.99 | 0.96 |
| Interest Burden | 1.08 | 1.22 | 1.14 | 1.20 | 1.09 |
| Research & Development to Revenue | 0.95 | 2.28 | 48.99 | 5.14 | 6.47 |
| SG&A to Revenue | 1.11 | 1.30 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.26 | 0.43 | 0.00 | 1.18 | 1.43 |
| Income Quality | 0.62 | 0.96 | 0.82 | 0.87 | 0.85 |
Currency in USD